Hans Eid - Ultimovacs ASA Chief Officer
| ULTI Stock | NOK 1.98 0.05 2.46% |
Insider
Hans Eid is Chief Officer of Ultimovacs ASA
| Phone | 47 41 38 00 80 |
| Web | https://ultimovacs.com |
Ultimovacs ASA Management Efficiency
The company has return on total asset (ROA) of (0.2021) % which means that it has lost $0.2021 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3318) %, meaning that it generated substantial loss on money invested by shareholders. Ultimovacs ASA's management efficiency ratios could be used to measure how well Ultimovacs ASA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | INSIDER Age | ||
| Gayle MBA | Bergenbio ASA | 68 | |
| James Barnes | Bergenbio ASA | N/A | |
| Akil Jackson | Bergenbio ASA | N/A | |
| Lucy Wabakken | PCI Biotech Holding | N/A | |
| Cristina MD | Bergenbio ASA | N/A | |
| Martin Olin | Bergenbio ASA | 54 | |
| Anders Hgset | PCI Biotech Holding | 69 | |
| Debbie Molyneux | Bergenbio ASA | N/A | |
| Kristin Eivindvik | PCI Biotech Holding | 62 | |
| Nigel MSc | Bergenbio ASA | N/A | |
| Alison Messom | Bergenbio ASA | 52 | |
Management Performance
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 |
Ultimovacs ASA Leadership Team
Elected by the shareholders, the Ultimovacs ASA's board of directors comprises two types of representatives: Ultimovacs ASA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ultimovacs. The board's role is to monitor Ultimovacs ASA's management team and ensure that shareholders' interests are well served. Ultimovacs ASA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ultimovacs ASA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antonius Berkien, Chief Officer | ||
| Pr Gaudernack, Chief Officer | ||
| Hans Eid, Chief Officer | ||
| Audun Tornes, Chief Officer | ||
| Gudrun Troite, Head Coordination | ||
| Anne Worsoe, Head Communication | ||
| Oivind Foss, Head Operations | ||
| Carlos Sousa, Chief Officer | ||
| Ingunn Westgaard, Head Research | ||
| Jens MD, Chief Officer |
Ultimovacs Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ultimovacs ASA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 3.35 B | |||
| Shares Outstanding | 34.4 M | |||
| Shares Owned By Insiders | 48.41 % | |||
| Shares Owned By Institutions | 24.83 % | |||
| Price To Book | 7.44 X | |||
| EBITDA | (161.69 M) | |||
| Net Income | (164.72 M) | |||
| Cash And Equivalents | 1.85 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.